AR
Argenx
ARGX·NASDAQBreda NLFounded 20081,800 employees
Large CapbiotechPublicImmunologyNeurologyHematology
Platform: FcRn Ab
Market Cap
$30B
All Drugs
8
Clinical Trials
13
Failed / Terminated
1
FDA Approved
1
Stock Price & Catalysts (ARGX)
Loading ARGX stock data...
Drug Pipeline (8 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| ARG-4339 | ARG-4339 | Phase 2 | 2 | BCL-2 | MDSSchizophrenia | ||
| ARG-314 | ARG-314 | Approved | 2 | Aβ | Endometrial Ca | ||
| ARG-3458 | ARG-3458 | Preclinical | 1 | RET | DravetCKD | ||
| Sovanaritide | ARG-8605 | Phase 3 | 1 | TNFα | TTR AmyloidosisMG | ||
| ARG-6988 | ARG-6988 | Preclinical | 1 | AuroraA | Wet AMD | ||
| ARG-1924 | ARG-1924 | Preclinical | 2 | DLL3 | SMADLBCL | ||
| ARG-3265 | ARG-3265 | Phase 1/2 | 2 | CD20 | MM | ||
| ARG-1250 | ARG-1250 | Phase 2 | 2 | C5 | Ewing Sarcoma |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (14)